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levels that correlated positively with
the hBD-2 levels. These observations
suggest a role for a gene–cytokine inter-
action in the occurrence of dermato-
phytosis, associating the infection with
decreased DEFB4 CN, and elevated
serum hBD-2 and IL-22 levels. The
authors hypothesize that the absence of
a correlation between DEFB4 CN varia-
tion and serum hBD-2 levels in patients
suggest that the genetic background is
the main factor controlling hBD-2 pro-
duction in the absence of infection,
whereas upregulation of expression by
T. rubrum, likely by stimulating IL-22
production, may cause the higher levels
that are seen in patients.
Among other hypotheses, the data pre-
sented by Jaradat et al. (2014) suggest that
low DEFB4 CN may be a risk factor for
dermatophytosis, with elevated IL-22
levels implicated in its pathogenesis.
More scientific contributions that pro-
vide new knowledge about the genetic
and other predisposing factors for der-
matophytosis are important because of
their implications for prophylaxis and
for therapy. Identifying individuals who
are susceptible to chronic dermato-
phytosis would allow for infection and
recurrence prevention. According to
Jaradat et al. (2014), patients with low
DEFB4 CN may be predisposed to all
dermatophytes, but a more chronic and
recalcitrant to treatment subtype like
onychomycosis could be prevented by
aggressive treatment of tinea pedis in
these patients. In addition, identifying
high-risk families would allow for
education of their members about the
risk of fungal infections. New thera-
peutic strategies can be developed as
well to target the altered immune res-
ponse pathways; considering this
article’s findings, one potential target
that merits exploration is IL-22.
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Metabolic Vulnerability in Melanoma:
A ME2 (Me Too) Story
Bin Zheng1 and David E. Fisher1
Metabolic reprograming is a hallmark of cancer and might represent an Achilles’
heel in cancer cells. The study by Chang et al. in this issue highlights a critical role
of mitochondrial malic enzyme 2 (ME2) in melanoma progression. Targeting ME2
could be an effective approach to inhibit melanoma cell proliferation and tumor
growth.
Journal of Investigative Dermatology (2015) 135, 657–659. doi:10.1038/jid.2014.449
Altered cellular metabolism is a hall-
mark of cancer. To successfully undergo
oncogenic transformation, cells must
meet the bioenergetic and biosynthetic
demands for growth and proliferation.
For example, most cancer cells have
increased uptake of glucose and glyco-
lytic flux to support the generation
of metabolic intermediates, such as
amino acids, nucleotides, and fatty
acids that are required to build a new
cell (Vander Heiden et al., 2009). In
addition to glucose, cancer cells often
use glutamine as another major nutrient
source and metabolize it through gluta-
minolysis to replenish the tricarboxylic
acid (TCA) cycle intermediates that
are utilized for various biosynthetic
reactions (Vander Heiden et al., 2009).
Importantly, expression and activity of
key enzymes in these metabolic path-
ways are regulated by various onco-
genes and tumor suppressors, providing
a mechanistic explanation for metabolic
reprograming in cancer. Understanding
the underlying mechanisms will there-
fore be critical to developing better
diagnostic tools and therapeutic strate-
gies for cancer, including melanoma,
where metabolic regulation was seen
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to interface with BRAF-targeted therapy
(Haq et al., 2014).
Malic enzymes (MEs) catalyze the
oxidative decarboxylation of malate, a
TCA cycle intermediate, to pyruvate,
with the concomitant reduction in
NAD(P)þ to NAD(P)H. There are three
isoforms of MEs in mammals with
different cofactor specificity and sub-
cellular localizations: the cytosolic
NADPþ -dependent ME1, the mitochon-
drial NAD(P)þ -dependent ME2, and
the mitochondrial NADPþ -dependent
ME3. Although the enzymatic acti-
vities of MEs have been well character-
ized in vitro (Chang and Tong, 2003),
very little is known about their bio-
logical roles, especially in the context
of cancer biology. In work reported in
this issue, Chang et al. (2014) examined
the expression of all three isoforms of
MEs in melanoma using microarray data
mining and IHC analysis. The authors
observed that both mRNA and protein
levels of ME2, but not of the other two
isoforms, increase during the progres-
sion from melanocytic nevi to malignant
melanoma (Chang et al., 2014), sug-
gesting a role of ME2 in melanoma
biology. Chang et al. (2014) further
demonstrated that shRNA-mediated
knockdown of ME2 in A375 (BRAF
V600E mutant) and A2058 (BRAF WT)
melanoma cells attenuated cell prolife-
ration. Moreover, knockdown of ME2 in
A2058 cells impaired their ability to
grow on soft agar and to develop xeno-
grafted tumors in non-obese diabetic/
severe combined immunodeficient mice
(Chang et al., 2014), suggesting that
ME2 is essential for the tumorigenicity
of these melanoma cell lines.
In addition to its role in regulating cell
proliferation and tumor growth, ME2
may also modulate senescence. Down-
regulation of ME2 was recently found to
induce senescence in IMR90 fibroblasts,
whereas expression of ME2 suppressed
senescence in these cells (Jiang et al.,
2013). In melanocytes, oncogenic BRAF
V600E is known to induce senescence,
and this process was recently suggested
to be associated with an increase in
pyruvate entry into the mitochondrial
TCA cycle (Kaplon et al., 2013). Intri-
guingly, enhanced expression of ME2
may have a similar metabolic effect as
BRAF V600E on the flux of pyruvate into
the TCA cycle, as ME2 converts malate
into pyruvate in mitochondria. Although
it is tempting to speculate that ME2
could regulate melanocyte senescence,
in part because of lower ME2 expression
levels in nevi (Chang et al., 2014), this
question awaits further investigation.
Using scratch wound healing and
matrigel-based invasion assays, Chang
et al. (2014) demonstrate that knock-
down of ME2 inhibited A2058 mela-
noma cell motility and invasion in vitro,
whereas ectopic expression of ME2
reversed this phenotype. ME2 expres-
sion did not impact metastatic potential
or overall survival in the tested cohort of
Chang et al. (2014), although a recent
study (Ren et al., 2014) reported eleva-
ted ME2 protein expression in metastatic
melanomas compared with primary
tumors, based on IHC analysis. Hence,
it remains to be seen whether ME2
expression can serve as a biomarker
for melanoma metastasis.
In this study, Chang et al. (2014) also
examined the metabolic consequence of
ME2 knockdown in melanoma cells.
ME2 may use either NAD or NADP as
a cofactor in the oxidative decarboxy-
lation reaction that generates NADH
or NAPDH, respectively. Because
NADH is the major donor for genera-
ting a proton gradient across the mito-
chondrial membrane, which, in turn,
is used to drive ATP production, it is
conceivable that ME2 may regulate
ATP production. Indeed, knockdown of
ME2 in melanoma cells reduced cellular
ATP levels (Chang et al., 2014). This
effect may, moreover, result from the
decreased generation of pyruvate from
malate, which may attenuate flux
through the TCA cycle. Furthermore,
knockdown of ME2 increased reactive
oxygen species (ROS) levels in mela-
noma cells (Chang et al., 2014), possibly
because of reducing the availablility of
NADPH to scavenge ROS. A reduction
in mitochondrial NADPH production
from ME2 could lead to an accumu-
lation of mitochondrial ROS. None-
theless, in-depth metabolic analyses,
such as stable isotope labeling and
metabolic flux analysis, would provide
additional insight into the metabolic
role of ME2 in melanoma.
An important finding in this study is
the negative regulation of AMP-acti-
vated protein kinase (AMPK) activity
by ME2 in melanoma. Chang et al.
(2014)found that knockdown of ME2
led to activation of the AMPK signaling
pathway, whereas ectopic expression
of ME2 was sufficient to inhibit AMPK.
As an evolutionarily conserved energy
sensor, AMPK regulates energy homeo-
stasis by monitoring changes in intra-
cellular AMP, ADP, and ATP concen-
trations (Hardie et al., 2012). Elevated
AMP (or ADP) to ATP ratios activate
AMPK and trigger it to phosphorylate
downstream effectors that stimulate
ATP-producing catabolic pathways,
while suppressing ATP-consuming bio-
synthetic pathways, thus maintaining an
energy balance (Hardie et al., 2012). In
addition to its well-established effect on
metabolism, AMPK has been shown to
regulate a variety of cellular processes,
including suppression of cell growth and
proliferation in response to metabolic
stress, supporting a potential tumor sup-
pressor role for AMPK. In this regard,
it is interesting to note that loss of
AMPKa1 expression was recently
reported to be associated with poor
overall and disease-specific 5-year
survival in a cohort of 128 melanoma
patients (Bhandaru et al., 2014). The
activation of AMPK can be triggered
by various metabolic stresses, such as
hypoxia, glucose deprivation, and ROS.
Thus, the decreased ATP production
and/or the increased ROS accumula-
Clinical Implications
 Expression of mitochondrial malic enzyme (ME2) increases during the
progression from melanocytic nevi to malignant melanoma.
 Knockdown of ME2 activates AMP-activated protein kinase and impaired
melanoma cell proliferation and tumor growth.
 Small molecule inhibitors of ME2 might be exploited for melanoma
therapy.
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tion from ME2 downregulation obser-
ved by Chang et al. (2014) could be
responsible for the AMPK activation.
Previously, the activity of AMPK in
melanoma was found to be repressed
by BRAF V600E mutant, a major driver
of melanoma (Zheng et al., 2009).
It would be interesting to determine
whether BRAF and ME2 coordinate in
attenuating AMPK activity in melanoma.
In addition, whether AMPK is indeed
a critical mediator of ME2’s effects on
cell proliferation and tumor growth in
melanoma needs to be addressed
experimentally.
The critical role of AMPK in suppres-
sing cell growth and proliferation raises
the interesting possibility that activation
of this pathway would suppress tumor
growth. More recently, phenformin, an
inhibitor of the mitochondria complex I
respiratory chain and an AMPK activa-
tor, was shown to enhance the anti-
tumor activitiy of BRAF inhibitors
in cultured melanoma cells and to
promote tumor regression in several
xenograft models and a genetically engi-
neered BRAF V600E–driven mouse
model of melanoma (Yuan et al.,
2013). Phenformin selectively targets a
minor subpopulation (approximately
5–10%) of melanoma cells expressing
JARID1B, a H3K4 demethylase and
marker for slow cycling cells, but
it has lower anti-tumor activity on the
JARID1B-negative cells (Yuan et al.,
2013). Conversely, although BRAF
inhibitors are effective in killing the
bulk of BRAF mutant melanoma
tumors––i.e., JARID1B-negative cells––
they do not appear to be effective
on JARID1B-positive cells (Yuan et al.,
2013). These results suggest that meta-
bolic heterogeneity exists in these
tumors, and this may contribute to
different states of treatment sensitivity
and resistance. The metabolic differen-
ces between these two subpopulations
of cells are still uncharacterized. It
certainly would be interesting to
investigate whether ME2 contributes to
this metabolic heterogeneity.
In summary, the work by Chang et al.
(2014) characterizes the function
of ME2 in melanoma, providing new
insight into metabolic reprograming
in melanoma. These findings suggest
a previously unknown vulnerability of
melanoma cells. If the catalytic activity
of ME2, indeed, proves to be critical
for the biological roles characterized in
this study, small molecule inhibitors of
ME2 might be exploited for melanoma
therapy.
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Unfolding the Mutational Landscape of
Human Melanoma
Diwakar Davar1, Yan Lin2 and John M. Kirkwood1
Over the preceding two decades, sophisticated sequencing techniques have
been used to characterize the genetic drivers of adult melanoma. However,
our understanding of pediatric melanomas is still rudimentary. In this report,
we comment on a thorough multi-platform analysis of common pediatric
melanoma subsets, including pediatric conventional melanoma (CM), congenital
nevus-derived melanoma (CNM), and Spitzoid melanoma (SM), contributed
by Lu et al.
Journal of Investigative Dermatology (2015) 135, 659–662. doi:10.1038/jid.2014.467
Data from whole-genome and -exome
sequencing (WGS/WES) and The Cancer
Genome Atlas (TCGA) have revealed
multiple new insights to the nature of
cutaneous melanoma, etiology, and
potential avenues of therapy. First, the
role of oral BRAF/MEK inhibitors (based
upon the frequency of B50% with UV
signature activating mutations in BRAF
and the MAPK pathway) has become
abundantly apparent. Further, the muta-
tional landscape and high frequency of
mutations observed in cutaneous mela-
noma, which exceeds those of all other
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